Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Nuvation Bio Inc. Director's Dealing 2023

Sep 22, 2023

32154_dirs_2023-09-21_a7738e7c-2928-4308-9e4a-2da7b034e857.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvation Bio Inc. (NUVB)
CIK: 0001811063
Period of Report: 2023-02-19

Reporting Person: NODELMAN OLEG (Director)
Reporting Person: EcoR1 Capital, LLC (Director)
Reporting Person: EcoR1 Capital Fund, L.P. (Director)
Reporting Person: EcoR1 Capital Fund Qualified, L.P. (Director)
Reporting Person: EcoR1 Venture Opportunity Fund, LP (Director)
Reporting Person: Biotech Opportunity GP, LLC (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-02-19 Class A Common Stock P 5143000 $1.2562 Acquired 12504675 Indirect
2023-02-20 Class A Common Stock P 117100 $1.362 Acquired 12621775 Indirect
2023-02-21 Class A Common Stock P 53000 $1.3611 Acquired 12674775 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Class A Common Stock 1169241 Indirect
Class A Common Stock 3165000 Indirect
Class A Common Stock 2200627 Indirect

Footnotes

F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2: Qualified Fund is the record holder of these securities.

F3: Capital Fund is the record holder of these securities.

F4: EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, Capital Fund, Qualified Fund and Venture Fund. Each of the reporting persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC but each reporting person disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.

F5: These securities are held of record by Venture Fund. Biotech indirectly beneficially owns these securities as the general partner of Venture Fund, and Mr. Nodelman indirectly beneficially owns these securities as the control person of Biotech and EcoR1.